Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Pre-mRNA splicing, crucial for gene expression, is mediated by the spliceosome.
• Aberrant splicing and mutations in spliceosome components like SF3B1 are linked to cancer.
• Small molecules targeting the spliceosome are investigated as anticancer agents.

Purpose of the Study:

• To investigate the molecular mechanisms of Jerantinine A (JA), a novel indole alkaloid with anti-proliferative activity.
• To determine if JA targets the spliceosome and its specific components in breast cancer cells.
• To elucidate the role of SF3B1 in JA's anticancer effects.

Main Methods:

• Pooled-genome wide shRNA library screening.
• Global proteomic profiling.
• Analysis of pre-mRNA splicing, cell death, and cell cycle arrest.
• SF3B1 protein stabilization and nucleosome complex dissociation assays.

Main Results:

• JA up-regulates SF3B1 and SF3B3 protein levels in breast cancer cells, indicating spliceosome targeting.
• JA induces tumor-specific cell death and increases unspliced pre-mRNAs.
• Depletion of SF3B1 abrogates JA-induced apoptosis but not cell cycle arrest.
• JA stabilizes SF3B1 and causes its dissociation from nucleosomes.

Conclusions:

• Jerantinine A (JA) exerts antitumor activity by targeting both tubulin polymerization and the spliceosome, specifically SF3B1 and SF3B3.
• SF3B1 is a key mediator of JA's apoptotic effects in breast cancer.
• JA's mechanism involves stabilizing SF3B1 and altering its cellular localization.